Loading…
Lantern Pharma Inc. is projected to rise to $6.50 by 2027, a +81% move from its current price of $3.60. LTRN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $3.42 | $3.60 | $3.80 | +0.08% |
| Jul 15 | $3.35 | $3.61 | $3.89 | +0.17% |
| Jul 16 | $3.29 | $3.61 | $3.96 | +0.25% |
| Jul 17 | $3.25 | $3.61 | $4.02 | +0.34% |
| Jul 18 | $3.21 | $3.62 | $4.07 | +0.42% |
| Jul 19 | $3.18 | $3.62 | $4.12 | +0.51% |
| Jul 20 | $3.15 | $3.62 | $4.17 | +0.59% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.15 | $3.62 | $4.17 | +0.59% |
| Week 2 | $2.99 | $3.64 | $4.44 | +1.19% |
| Week 3 | $2.87 | $3.66 | $4.67 | +1.78% |
| Week 4 | $2.78 | $3.69 | $4.88 | +2.39% |
| Week 5 | $2.71 | $3.71 | $5.08 | +2.99% |
| Week 6 | $2.64 | $3.73 | $5.26 | +3.60% |
| Week 7 | $2.59 | $3.75 | $5.44 | +4.21% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lantern Pharma Inc. is a healthcare company focused on the discovery and development of oncology drugs in India. Its product pipeline includes LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.
The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc.
that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Lantern Pharma Inc. (LTRN) is a healthcare stock trading in the small-cap space with current price data showing $3.60 per share and a market capitalization of $45.93M. It sits at rank 4570 by market cap.
The stock’s price outlook is skewed toward upside, with a multi-year forecast that envisions higher average prices in the years ahead, starting from the 2026 level of $3.60 and extending to substantially higher levels by 2050. These are estimates and not guarantees. The pipeline and partnerships suggest continued development activity in oncology across multiple candidates and collaboration agreements.
A major floor 68.9% below — a decisive break under it would weaken the trend.
The nearest floor, 13.9% below — buyers have tended to step in here.
The nearest ceiling, 15.8% above — a clean break opens room to run.
A major ceiling 30.4% above — clearing it would confirm fresh momentum.
Key LTRN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LTRN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.51 | Buy | $3.54 | Buy |
| MA 10 | $3.76 | Sell | $3.65 | Sell |
| MA 20 | $3.81 | Sell | $3.69 | Sell |
| MA 50 | $3.31 | Buy | $3.41 | Buy |
| MA 100 | $2.82 | Buy | $3.19 | Buy |
| MA 200 | $3.21 | Buy | $3.23 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.25 | Neutral |
| Stoch RSI (14) | 45.27 | Neutral |
| CCI (20) | -73.68 | Neutral |
| Williams %R (14) | -53.27 | Info |
| MACD (12,26,9) | -0.10 | Sell |
| ROC (12) | -6.01 | Sell |
| Bollinger %B (20,2) | 0.29 | Neutral |
| Stochastic %K (14) | 46.73 | Neutral |
| TRIX (15) | 0.57 | Buy |
| Awesome (5,34) | -0.21 | Sell |
| Ultimate (7,14,28) | 38.60 | Neutral |
| Momentum (10) | -0.07 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 3.20 | Buy |
| ADX (14) | 19.47 | Neutral |
| ATR (14) | 0.18 | Info |
The 30-day technical picture is bullish, supported by a neutral RSI reading of 50. The near-term trend is reflected in the moving averages, with a SMA50 of $3.31 and a SMA200 of $3.21. Near-term support is cited at $3.10, with resistance at $4.17.
Over the last 30 days, the price has ranged from a low of $2.54 to a high of $5.11, illustrating notable intra-month volatility as investors weigh the potential of the company’s pipeline.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.12 | $3.60 | $5.64 | 0% | Neutral | |
| $4.72 | $6.50 | $9.68 | +81% | Bullish | |
| $6.39 | $9.34 | $14.82 | +160% | Bullish | |
| $6.20 | $9.55 | $15.90 | +165% | Bullish | |
| $6.43 | $10.39 | $17.99 | +189% | Bullish | |
| $6.95 | $11.72 | $21.02 | +226% | Bullish | |
| $6.93 | $12.18 | $22.51 | +238% | Bullish | |
| $10.79 | $19.76 | $37.54 | +449% | Bullish | |
| $12.70 | $24.17 | $47.09 | +571% | Bullish | |
| $11.98 | $23.71 | $47.25 | +559% | Bullish | |
| $20.99 | $46.65 | $102.15 | +12.0x | Bullish | |
| $36.23 | $80.51 | $185.18 | +21.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.12 | $3.60 | $4.53 | +0.00% |
| August 2026 | $3.02 | $3.65 | $4.61 | +1.49% |
| September 2026 | $3.17 | $3.89 | $5.00 | +6.39% |
| October 2026 | $3.44 | $4.27 | $5.59 | +9.86% |
| November 2026 | $3.38 | $4.24 | $5.64 | -0.62% |
| December 2026 | $3.30 | $4.19 | $5.64 | -1.26% |
Click any year to see its month-by-month LTRN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect LTRN to range from $1.12 to $5.64 through 2026. The $3.60 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The LTRN price prediction for 2027 points to an average of $6.50 (low $4.72, high $9.68) — a potential gain of +81% on today's $3.60. Momentum favours further upside here.
In 2028, LTRN is projected to trade between $6.39 and $14.82, averaging $9.34 — a potential gain of +160% from today's $3.60. That is up +44% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Lantern Pharma Inc.'s 2029 outlook centres on $9.55, within a $6.20 to $15.90 range. That is up +2% on the projected 2028 average. That marks a +165% change versus current levels. Momentum favours further upside here.
By 2030, LTRN could reach as high as $17.99, with a base case around $10.39 and support toward $6.43 — roughly +189% from $3.60. Buyers look set to stay in control over this stretch.
Expect LTRN to range from $6.95 to $21.02 through 2031. The $11.72 average target implies a +226% move from current prices. That is up +13% on the projected 2030 average. Momentum favours further upside here.
The LTRN price prediction for 2032 points to an average of $12.18 (low $6.93, high $22.51) — a potential gain of +238% on today's $3.60. Buyers look set to stay in control over this stretch.
In 2033, LTRN is projected to trade between $10.79 and $37.54, averaging $19.76 — a potential gain of +449% from today's $3.60. That is up +62% on the projected 2032 average. Momentum favours further upside here.
Lantern Pharma Inc.'s 2034 outlook centres on $24.17, within a $12.70 to $47.09 range. That is up +22% on the projected 2033 average. That marks a +571% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, LTRN could reach as high as $47.25, with a base case around $23.71 and support toward $11.98 — roughly +559% from $3.60. Momentum favours further upside here.
Expect LTRN to range from $20.99 to $102.15 through 2040. The $46.65 average target implies a +12.0x move from current prices. That is up +97% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The LTRN price prediction for 2050 points to an average of $80.51 (low $36.23, high $185.18) — a potential gain of +21.4x on today's $3.60. Momentum favours further upside here.
Investing $1,000 in LTRN today (≈ 277.777778 LTRN) could be worth
$22,364.66
+$21,364.66 (+2136%) by 2050 · US Dollar
Based on the average projected LTRN price of $80.51 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LTRNwould be worth at today's price.
$1,000 invested in LTRN on Jul 10, 2025 (≈ 284.900286 LTRN) would be worth
$1,025.64
+$25.64 (+2.6%) today · 1.03× · US Dollar
Based on a LTRN entry price of $3.51 vs. today's $3.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.97 | $906.8 | -9.3% |
| 1 month ago | $3.88 | $927.84 | -7.2% |
| 3 months ago | $1.97 | $1,827.41 | +82.7% |
| 6 months ago | $3.36 | $1,071.43 | +7.1% |
| 1 year ago | $3.51 | $1,025.64 | +2.6% |
| All time (5.0y) ago | $13.3 | $270.68 | -72.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LTRN forecast.
Our base-case forecast reaches $7.20 around 2028.
Implied market cap at $7.20: $91.87M
The multi-year forecast shows a bullish trajectory with rising average prices and meaningful upside. In 2026 the average is $3.60 with a 0% ROI, followed by continued upside through 2027 ($6.52 avg, 81.2% ROI) and 2028 ($9.33 avg, 159.3% ROI). The 2029 projection is $9.56 on average with 165.5% ROI, and 2030 reaches $10.39 on average with 188.7% ROI.
The forecast continues higher in 2031 ($11.71 avg, 225.2% ROI) and 2032 ($12.21 avg, 239.1% ROI). By 2033 the avg rises to $19.78 with a 449.6% ROI, and 2034 to $24.14 with 570.6% ROI, followed by 2035 at $23.73 with 559.1% ROI. The horizon strengthens further in 2040, with an average of $46.62 and a 1,195% ROI, and by 2050 the average is $80.60 with a 2,138.9% ROI.
These figures reflect bullish sentiment for the longer term, though they are estimates and not guarantees.
Tap a question to reveal the answer.
The forecast shows an avg price of $10.39 with a min of $6.44 and a max of $18.01, and a projected ROI of 188.7%. The sentiment for 2030 is BULLISH.
Forecasts show bullish sentiment in several years beyond 2026, with higher averages and ROIs (e.g., 2027 avg $6.52, ROI 81.2%; 2030 avg $10.39, ROI 188.7%; 2050 avg $80.60, ROI 2138.9%). However, the 2026 figure carries a 0% ROI and these estimates are not guarantees.
Yes. The max forecast for 2040 is $102.08 and for 2050 is $185.38, indicating the potential to surpass $100 within the forecast horizon.
Current price is $3.60 and market capitalization is $45.93M.
The 30-day range is a low of $2.54 and a high of $5.11.
Lantern Pharma Inc. Community Discussion
0Share your Lantern Pharma Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.